Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Transactions

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of common stock on February 23 and 26, 2024.

Summary

• Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reported changes in beneficial ownership of the company's stock.
• On February 23, 2024, 828 shares of common stock were disposed of at a price of $431.79 per share.
• On February 26, 2024, 883 shares of common stock were sold at a price of $425.7 per share.
• Following these transactions, Ms. Ambrose directly owns 7,965 shares of Vertex Pharmaceuticals common stock.
• The initial transaction on February 23, 2024 was a disposition of shares to cover tax obligations related to vesting of restricted stock units.
• The transactions were made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on February 28, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of company leadership.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates